Targeted Drug for Advanced Pancreatic Cancer Sparks Early Enthusiasm

(MedPage Today) — SAN FRANCISCO — Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease control with a novel KRAS G12D inhibitor, a small preliminary study showed.
The early results showed that…